Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer

BOSTON, Sept. 14, 2022 /PRNewswire/ -- Biolojic Design, a pioneer in the use of artificial intelligence (AI) in antibody design, today announced the appointment of Ronald Herbst, Ph.D. as Chief Scientific Officer, effective October 3, 2022.  A 28-year industry veteran with a proven track record of scientific leadership in Big Pharma and small publicly traded biotechnology companies, Dr. Herbst joins Biolojic Design as the company is expanding its U.S. operations and advancing more computationally designed, smart antibodies into the clinic.